Moclobemide in the treatment of social phobia.

Abstract

Social phobia is a common disorder which is associated with considerable suffering and impairment. Effective treatments have now been developed and they represent an important advance in the management of the disorder. Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) which has an established place in the treatment of depression. The efficacy of moclobemide in social phobia has been demonstrated in short-term treatment for up to 12 weeks in three placebo-controlled studies. It has also proved to be effective in long-term treatment in a placebo-controlled study and in open treatment studies. This paper reviews the efficacy of moclobemide in social phobia.

• Authors: D Nutt, S A Montgomery
• Journal: International clinical psychopharmacology (Int Clin Psychopharmacol) Vol. 11 Suppl 3 Pg. 77-82 (Jun 1996) ISSN: 0268-1315 [Print] England
• PMID: 8923114 (Publication Type: Comparative Study, Journal Article, Review)

Chemical References

• Benzamides
• Monoamine Oxidase Inhibitors
• Moclobemide

Topics

• Benzamides (therapeutic use)
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Humans
• Moclobemide
• Monoamine Oxidase Inhibitors (therapeutic use)
• Phobic Disorders (drug therapy)